FindTrial
Sign In

A prospective, randomized, investigator-blind, controlled, clinical study of phase III on the clinical efficacy and tolerability of hMG-IBSA IBSA Institut Biochimique sa versus Menopur Ferring administered subcutaneously in women undergoing controlled ovarian hyperstimulation COH in an ART programme IVF .

A prospective, randomized, investigator-blind, controlled, clinical study of phase III on the clinical efficacy and tolerability of hMG-IBSA IBSA Institut Biochimique sa versus Menopur Ferring administered subcutaneously in women undergoing controlled ovarian hyperstimulation COH in an ART programme IVF .

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000993-29-IT
Enrollment
Unknown
Registered
2007-01-19
Start date
2005-07-19
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COH Controlled Ovarian Hyperstimulation in ART Assisted Reproductive Technology /IVF MedDRA version: 6.1 Level: PT Classification code 10056204

Interventions

Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Human menopausal gonadotrophin CAS Number: 9002-68-0 Concentration unit: IU international unit(s) Concentration

Sponsors

IBSA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026